Search Results - "STEPAN, J"

Teriparatide for osteoporosis: importance of the full course by Lindsay, R., Krege, J. H., Marin, F., Jin, L., Stepan, J. J.

“…Teriparatide (TPTD) is the only currently available therapeutic agent that increases the formation of new bone tissue and can provide some remediation of the…”
Get full text

Update on Menopausal Hormone Therapy for Fracture Prevention by Stepan, Jan J., Hruskova, Hana, Kverka, Miloslav

“…Purpose of Review The goal of the review is to assess the appropriateness of menopausal hormone therapy (MHT) for the primary prevention of bone loss in women…”
Get full text

Cortical thickness mapping to identify focal osteoporosis in patients with hip fracture by Poole, Kenneth E S, Treece, Graham M, Mayhew, Paul M, Vaculík, Jan, Dungl, Pavel, Horák, Martin, Štěpán, Jan J, Gee, Andrew H

“…Individuals with osteoporosis are predisposed to hip fracture during trips, stumbles or falls, but half of all hip fractures occur in those without generalised…”
Get full text

Strontium ranelate: in search for the mechanism of action by Stepan, Jan J.

“…Strontium ranelate is a medicine with evidenced effects on the risk of fractures. The heterogeneity of strontium distribution in bone, quality of bone mineral…”
Get full text

Osteoporosis in young adults: pathophysiology, diagnosis, and management by Ferrari, S., Bianchi, M. L., Eisman, J. A., Foldes, A. J., Adami, S., Wahl, D. A., Stepan, J. J., de Vernejoul, M.-C., Kaufman, J.-M.

“…Postmenopausal osteoporosis is mainly caused by increased bone remodeling resulting from estrogen deficiency. Indications for treatment are based on low areal…”
Get full text

Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study by Reginster, J-Y, Adami, S, Lakatos, P, Greenwald, M, Stepan, J J, Silverman, S L, Christiansen, C, Rowell, L, Mairon, N, Bonvoisin, B, Drezner, M K, Emkey, R, Felsenberg, D, Cooper, C, Delmas, P D, Miller, P D

“…Background: Reducing bisphosphonate dosing frequency may improve suboptimal adherence to treatment and therefore therapeutic outcomes in postmenopausal…”
Get full text

Effects of Teriparatide Compared with Risedronate on the Risk of Fractures in Subgroups of Postmenopausal Women with Severe Osteoporosis: The VERO Trial by Geusens, Piet, Marin, Fernando, Kendler, David L, Russo, Luis A, Zerbini, Cristiano AF, Minisola, Salvatore, Body, Jean Jacques, Lespessailles, Eric, Greenspan, Susan L, Bagur, Alicia, Stepan, Jan J, Lakatos, Péter, Casado, Enrique, Moericke, Rüdiger, López‐Romero, Pedro, Fahrleitner‐Pammer, Astrid

“…ABSTRACT The 2‐year, randomized, double‐blind, active‐controlled fracture endpoint VERO study included postmenopausal women with established osteoporosis, who…”
Get full text

Acute Effects of Glucocorticoids on Serum Markers of Osteoclasts, Osteoblasts, and Osteocytes by Brabnikova Maresova, Kristyna, Pavelka, Karel, Stepan, Jan J.

“…The aim of this study was to investigate the acute effects of oral glucocorticoids in doses used in clinical practice on biochemical indices of the function of…”
Get full text

Vitamin D and calcium supplementation for three years in postmenopausal osteoporosis significantly alters bone mineral and organic matrix quality by Paschalis, E.P, Gamsjaeger, S, Hassler, N, Fahrleitner-Pammer, A, Dobnig, H, Stepan, J.J, Pavo, I, Eriksen, E.F, Klaushofer, K

“…Abstract Prospective, controlled clinical trials in postmenopausal osteoporosis typically compare effects of an active drug with placebo in addition to vitamin…”
Get full text

A decrease in serum 1,25(OH)2D after elective hip replacement and during bone healing is associated with changes in serum iron and plasma FGF23 by Vaculik, J., Wenchich, L., Bobelyak, M., Pavelka, K., Stepan, J. J.

“…Objective Although calcitriol is essential for bone healing, its serum concentrations are low after hip surgery, and they continue to decline during bone…”
Get full text

A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis by Lekamwasam, S., Adachi, J. D., Agnusdei, D., Bilezikian, J., Boonen, S., Borgström, F., Cooper, C., Diez Perez, A., Eastell, R., Hofbauer, L. C., Kanis, J. A., Langdahl, B. L., Lesnyak, O., Lorenc, R., McCloskey, E., Messina, O. D., Napoli, N., Obermayer-Pietsch, B., Ralston, S. H., Sambrook, P. N., Silverman, S., Sosa, M., Stepan, J., Suppan, G., Wahl, D. A., Compston, J. E.

“…Summary This paper provides a framework for the development of national guidelines for the management of glucocorticoid-induced osteoporosis in men and women…”
Get full text

Characterization of opioid consumption and disposal patterns after total knee arthroplasty by Premkumar, A, Lovecchio, F C, Stepan, J G, Sculco, P K, Jerabek, S A, Gonzalez Della Valle, A, Mayman, D J, Pearle, A D, Alexiades, M M, Albert, T J, Cross, M B, Haas, S B

“…AimsThe aim of this study was to determine the general postoperative opioid consumption and rate of appropriate disposal of excess opioid prescriptions in…”
Get full text

Decrease in serum calcitriol (but not free 25-hydroxyvitamin D) concentration in hip fracture healing by Vaculik, J., Wenchich, L., Bobelyak, M., Pavelka, K., Stepan, J. J.

“…Objective To assess the decrease in serum calcitriol concentrations after hip fracture. Methods Serum concentrations of calcitriol, 25(OH)D, parathyroid…”
Get full text

Effects of morning vs. evening teriparatide injection on bone mineral density and bone turnover markers in postmenopausal osteoporosis by Michalska, D., Luchavova, M., Zikan, V., Raska, I., Kubena, A. A., Stepan, J. J.

“…Summary A 12-month morning teriparatide (TPTD) administration resulted in a larger increase in the lumbar spine bone mineral density (BMD) than the evening…”
Get full text

Menopausal Transition: Prospective Study of Estrogen Status, Circulating MicroRNAs, and Biomarkers of Bone Metabolism by Baloun, Jiri, Pekacova, Aneta, Wenchich, Laszlo, Hruskova, Hana, Senolt, Ladislav, Svec, Xiao, Pavelka, Karel, Stepan, Jan J

“…Osteoporosis is associated with an impaired balance between bone resorption and formation, which in turn leads to bone loss and fractures. Many recent studies…”
Get full text

Efficacy of teriparatide compared with risedronate on FRAX®-defined major osteoporotic fractures: results of the VERO clinical trial by Body, J.-J., Marin, F., Kendler, D.L., Zerbini, C.A.F., López-Romero, P., Möricke, R., Casado, E., Fahrleitner-Pammer, A., Stepan, J.J., Lespessailles, E., Minisola, S., Geusens, P.

“…Summary FRAX ® calculates the 10-year probability of major osteoporotic fractures (MOF), which are considered to have a greater clinical impact than other…”
Get full text

Effects of Teriparatide Compared with Risedronate on Recovery After Pertrochanteric Hip Fracture: Results of a Randomized, Active-Controlled, Double-Blind Clinical Trial at 26 Weeks by Aspenberg, Per, Malouf, Jorge, Tarantino, Umberto, García-Hernández, Pedro A., Corradini, Costantino, Overgaard, Søren, Stepan, Jan J., Borris, Lars, Lespessailles, Eric, Frihagen, Frede, Papavasiliou, Kyriakos, Petto, Helmut, Caeiro, José Ramón, Marin, Fernando

“…Osteoporosis drugs might affect fracture-healing. We therefore studied the effects of teriparatide in comparison with risedronate on recovery after…”
Get full text

Interindividual differences contribute to variation in microbiota composition more than hormonal status: A prospective study by Jackova, Zuzana, Stepan, Jan J, Coufal, Stepan, Kostovcik, Martin, Galanova, Natalie, Reiss, Zuzana, Pavelka, Karel, Wenchich, Laszlo, Hruskova, Hana, Kverka, Miloslav

“…Ovarian hormone deficiency is one of the main risk factors for osteoporosis and bone fractures in women, and these risks can be mitigated by menopausal hormone…”
Get full text

Histomorphometric changes by teriparatide in alendronate-pretreated women with osteoporosis by Stepan, J. J, Burr, D. B, Li, J, Ma, Y. L, Petto, H, Sipos, A, Dobnig, H, Fahrleitner-Pammer, A, Michalská, D, Pavo, I

“…Summary The level of increased bone formation after 24 months of treatment with teriparatide (rhPTH (1-34), TPTD) is similar in patients who were either…”
Get full text

Multinational, Placebo-Controlled, Randomized Trial of the Effects of Alendronate on Bone Density and Fracture Risk in Postmenopausal Women with Low Bone Mass: Results of the FOSIT Study by Pols, H. A. P., Felsenberg, D., Hanley, D. A., Štepán, J., Muñoz-Torres, M., Wilkin, T. J., Qin-sheng, G., Galich, A. M., Vandormael, K., Yates, A. J., Stych, B.

“…This randomized, double-masked, placebo-controlled trial evaluated the safety, tolerability and effects on bone mineral density (BMD) of alendronate in a…”
Get full text